(ACB) Aurora Cannabis - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 205m USD | Total Return: -34.8% in 12m
Avg Turnover: 2.29M
Qual. Beats: 0
Rev. Trend: 97.6%
Qual. Beats: 0
Warnings
Interest Coverage Ratio 0.0 is critical
Altman Z'' -15.00 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
Aurora Cannabis Inc. (ACB) is a Canadian pharmaceutical and plant propagation company that produces, distributes, and sells medical and consumer cannabis products globally. Headquartered in Edmonton, the company operates a diverse brand portfolio including San Rafael 71 and MedReleaf, offering products ranging from dried flower and oils to ingestibles and topicals.
The company maintains a dual-segment business model, combining high-margin medical cannabis sales with a plant propagation division focused on vegetables and floral plants. While the Canadian recreational market remains highly competitive, Aurora has increasingly shifted its strategic focus toward international medical markets, such as Germany and Australia, where regulatory barriers often result in higher price points compared to the adult-use sector.
A closer look at ValueRay can help clarify how these international shifts impact long-term valuation.
- International medical cannabis export growth drives high-margin revenue expansion
- Canadian adult-use market saturation and price compression impact domestic profitability
- Global regulatory shifts and German legalization progress influence investor sentiment
- Bevo Farms acquisition diversifies revenue through plant propagation and vegetable production
- Debt reduction and cost-cutting measures aim for consistent positive free cash flow
| Net Income: -42.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.04 > 0.02 and ΔFCF/TA -0.68 > 1.0 |
| NWC/Revenue: 82.55% < 20% (prev 107.5%; Δ -24.95% < -1%) |
| CFO/TA -0.01 > 3% & CFO -9.60m > Net Income -42.5m |
| Net Debt (31.8m) to EBITDA (24.2m): 1.31 < 3 |
| Current Ratio: 3.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (57.3m) vs 12m ago 2.82% < -2% |
| Gross Margin: 49.49% > 18% (prev 0.68%; Δ 4.88k% > 0.5%) |
| Asset Turnover: 44.27% > 50% (prev 36.97%; Δ 7.30% > 0%) |
| Interest Coverage Ratio: 0.03 > 6 (EBITDA TTM 24.2m / Interest Expense TTM 8.43m) |
| A: 0.39 (Total Current Assets 445.8m - Total Current Liabilities 145.9m) / Total Assets 775.3m |
| B: -8.26 (Retained Earnings -6.40b / Total Assets 775.3m) |
| C: 0.00 (EBIT TTM 216k / Avg Total Assets 820.6m) |
| D: 2.59 (Book Value of Equity 536.4m / Total Liabilities 207.5m) |
| Altman-Z'' = -21.68 = D |
| DSRI: 0.79 (Receivables 44.2m/49.5m, Revenue 363.3m/320.2m) |
| GMI: 1.37 (GM 49.49% / 67.74%) |
| AQI: 0.77 (AQ_t 0.09 / AQ_t-1 0.12) |
| SGI: 1.13 (Revenue 363.3m / 320.2m) |
| TATA: -0.04 (NI -42.5m - CFO -9.60m) / TA 775.3m) |
| Beneish M = -2.95 (Cap -4..+1) = A |
As of May 30, 2026, the stock is trading at USD 3.60 with a total of 790,389 shares traded.
Over the past week, the price has changed by +1.12%,
over one month by +9.42%,
over three months by -6.25% and
over the past year by -34.78%.
Aurora Cannabis has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy ACB.
- StrongBuy: 3
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 6.3 | 75.3% |
Market Cap CAD = 281.9m (204.6m USD * 1.3781 USD.CAD)
P/E Forward = 19.1571
P/S = 0.5483
P/B = 0.5274
Revenue TTM = 363.3m CAD
EBIT TTM = 216k CAD
EBITDA TTM = 24.2m CAD
Long Term Debt = 40.2m CAD (from longTermDebt, last fiscal year)
Short Term Debt = 67.8m CAD (from shortTermDebt, last quarter)
Debt = 140.2m CAD (from shortLongTermDebtTotal, last quarter) + Leases 39.2m
Net Debt = 31.8m CAD (calculated: Debt 140.2m - CCE 108.5m)
Enterprise Value = 313.7m CAD (281.9m + Debt 140.2m - CCE 108.5m)
Interest Coverage Ratio = 0.03 (Ebit TTM 216k / Interest Expense TTM 8.43m)
EV/FCF = -10.03x (Enterprise Value 313.7m / FCF TTM -31.3m)
FCF Yield = -9.97% (FCF TTM -31.3m / Enterprise Value 313.7m)
FCF Margin = -8.61% (FCF TTM -31.3m / Revenue TTM 363.3m)
Net Margin = -11.71% (Net Income TTM -42.5m / Revenue TTM 363.3m)
Gross Margin = 49.49% ((Revenue TTM 363.3m - Cost of Revenue TTM 183.5m) / Revenue TTM)
Gross Margin QoQ = 49.50% (prev 35.73%)
Tobins Q-Ratio = 0.40 (Enterprise Value 313.7m / Total Assets 775.3m)
Interest Expense / Debt = 6.01% (Interest Expense 8.43m / Debt 140.2m)
Taxrate = 22.66% (4.62m / 20.4m)
NOPAT = 167k (EBIT 216k * (1 - 22.66%))
Current Ratio = 3.06 (Total Current Assets 445.8m / Total Current Liabilities 145.9m)
Debt / Equity = 0.26 (Debt 140.2m / totalStockholderEquity, last quarter 536.4m)
Debt / EBITDA = 1.31 (Net Debt 31.8m / EBITDA 24.2m)
Debt / FCF = -1.02 (negative FCF - burning cash) (Net Debt 31.8m / FCF TTM -31.3m)
Total Stockholder Equity = 546.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -5.18% (Net Income -42.5m / Total Assets 775.3m)
RoE = -0.61% (Net Income TTM -42.5m / Total Stockholder Equity 6.95b)
RoCE = 0.00% (EBIT 216k / Capital Employed (Equity 6.95b + L.T.Debt 40.2m))
RoIC = 0.03% (NOPAT 167k / Invested Capital 642.4m)
WACC = 8.21% (E(281.9m)/V(422.1m) * Re(9.98%) + D(140.2m)/V(422.1m) * Rd(6.01%) * (1-Tc(0.23)))
Discount Rate = 9.98% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 74.00 | Cagr: 19.50%
[DCF] Fair Price = unknown (Cash Flow -31.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.32 | # QB: 0
Revenue Correlation: 97.61 | Revenue CAGR: 17.20% | SUE: 0.07 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.08 | Chg30d=N/A | Revisions=N/A | Analysts=1